10:25:02 EST Wed 18 Nov 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Z:LLY - ELI LILLY AND COMPANY - https://www.lilly.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LLY - Z1.01,403.23·1,405.000.11,404.66-10.77-0.8540.1758,29013,4551,409.87  1,423.11  1,399.081,475.25  850.5110:08:01Nov 1415 min RT 2¢

Recent Trades - Last 10 of 13455
Time ETExPriceChangeVolume
10:08:11Z1,404.7303-10.81971
10:08:11Z1,404.1267-11.3033150
10:08:10Z1,401.4889-14.06112
10:08:10Z1,404.11-11.441
10:08:10Z1,404.6046-10.94543
10:08:09Z1,403.23-12.2011
10:08:09Z1,404.98-10.571
10:08:09Z1,404.105-11.4451
10:08:09Z1,404.105-11.4451
10:08:08Z1,404.105-11.32510

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-11-14 12:01U:LLYNews ReleaseLilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
2026-11-12 15:30U:LLYNews ReleaseLilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
2026-11-11 09:45U:LLYNews ReleaseNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
2026-11-10 08:00U:LLYNews ReleaseLife doesn't slow down, and Foundayo(TM) (orforglipron) patient Leanne Morgan is done waiting
2026-11-09 09:30U:LLYNews ReleaseLilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
2026-11-09 08:00U:LLYNews ReleaseGabelli Releases Agenda for 8th Annual Healthcare Symposium
2026-11-06 06:47U:LLYNews ReleaseLilly and Hims & Hers expand access to FDA-approved Lilly medicines
2026-11-05 06:45U:LLYNews ReleaseLilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
2026-11-03 09:00U:LLYNews ReleasePeptide Therapies Are Changing the Future of Medicine - And the Market Could Reach $335 Billion
2026-10-29 09:00U:LLYNews ReleaseThe $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
2026-10-29 06:45U:LLYNews ReleaseLilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
2026-10-28 06:45U:LLYNews ReleaseLilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
2026-10-27 16:03U:LLYNews ReleasePatrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets
2026-10-26 11:19U:LLYNews ReleaseLilly declares fourth-quarter 2026 dividend
2026-10-25 03:30U:LLYNews ReleaseNew data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
2026-10-24 02:30U:LLYNews ReleaseLilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRalpha-targeting ADC at ESMO 2026
2026-10-22 10:30U:LLYNews ReleaseLilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
2026-10-19 04:40U:LLYNews ReleaseLilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
2026-10-18 18:05U:LLYNews ReleaseLilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress